Physician profile
Peter Lontai
NPI 1821192030
$7,726.85
in general payments reported to CMS, 2019-2025
31 companies · $556 in 2025
The $556 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,823 · 2020: $1,663 · 2021: $1,173 · 2022: $877 · 2023: $907 · 2024: $728 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,191.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,220.58 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amarin Pharma, INC. | $695.13 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $555.16 | 2019-2023 | Livalo, Seglentis |
| Lilly USA, LLC | $552.46 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $522.15 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $514.55 | 2019-2025 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $475.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mannkind Corporation | $459.40 | 2019-2025 | Afrezza |
| Abbvie INC. | $357.46 | 2021-2025 | |
| Glaxosmithkline, LLC. | $340.85 | 2019-2025 | Trelegy Ellipta, Bexsero |
| Pfizer INC. | $340.24 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $336.57 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $181.48 | 2019-2021 | |
| Qiagen, LLC | $164.89 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $146.00 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $141.96 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $100.98 | 2019-2020 | |
| Horizon Therapeutics Plc | $93.68 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.35 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.67 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $65.50 | 2023-2024 | Edarbyclor, Edarbyclor, Edarbi |
| Philips North America LLC | $52.19 | 2022 | |
| Alkermes, INC. | $48.85 | 2020-2025 | Vivitrol |
| Novartis Pharmaceuticals Corporation | $40.41 | 2021-2022 | |
| Esperion Therapeutics, INC. | $31.85 | 2020-2024 | Nexletol |
| Amgen INC. | $30.29 | 2023-2024 | Otezla, Repatha |
| Genentech USA, INC. | $27.80 | 2019 | |
| Indivior INC. | $24.50 | 2019 | |
| Insulet Corporation | $23.08 | 2025 | Omnipod |
| Medicure Pharma INC. | $15.00 | 2021 | |
| Ironwood Pharmaceuticals, INC | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lontai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.